☆ 4.7 Review

HHLA2 immune-regulatory roles in cancer

BIOMEDICINE & PHARMACOTHERAPY (2023)

Related references

Note: Only part of the references are listed.

Article Pathology

HHLA2 Immune Checkpoint Is a Novel Prognostic Predictor in Hepatocellular Carcinoma

Xiaoyan Liao et al.

Summary: The study found that HHLA2 is frequently expressed in hepatocellular carcinoma (HCC) and is associated with higher CD8+ cell density and favorable prognosis. Patients with co-expression of HHLA2 and high CD8+ cell density showed the most favorable prognosis among HCC patients.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2022)

Add to Collection

Article Immunology

Different clinical significance of novel B7 family checkpoints VISTA and HHLA2 in human lung adenocarcinoma

Long Long et al.

Summary: This study revealed that high expression of VISTA and HHLA2 in lung adenocarcinoma is associated with poor prognosis and survival.

IMMUNOTHERAPY (2022)

Add to Collection

Article Cell Biology

HHLA2 Activates the JAK/STAT Signaling Pathway by Binding to TMIGD2 in Hepatocellular Carcinoma Cells

Hui Guo et al.

Summary: The study reveals that HHLA2 is associated with TMIGD2 in hepatocellular carcinoma (HCC). Overexpression of HHLA2 inhibits T cell proliferation and activation, while activating the JAK/STAT pathway, thus promoting immune tolerance in HCC cells.

INFLAMMATION (2022)

Add to Collection

Article Biotechnology & Applied Microbiology

HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer

Zeng Yang et al.

Summary: This study analyzed the expression of HHLA2 in various cancers and its correlation with prognosis and immune infiltrate function. The results showed that HHLA2 was aberrantly expressed in multiple cancers and was associated with survival, pathological stage, tumor mutation burden, immune cell infiltration, and immune checkpoint genes. Additionally, HHLA2 expression was related to tumor microenvironment and signaling pathways.

BIOMED RESEARCH INTERNATIONAL (2022)

Add to Collection

Article Immunology

Coexpression of HHLA2 and PD-L1 on Tumor Cells Independently Predicts the Survival of Spinal Chordoma Patients

Chao Xia et al.

Summary: This study investigated the expression of PD-L1, HHLA2, B7H3, IDO-1, and Galectin-9 in spinal chordoma and their association with tumor infiltrating lymphocytes, clinicopathological characteristics, and patient survival. The results showed that HHLA2 and PD-L1 were commonly expressed in spinal chordoma and their coexpression independently predicted worse local recurrence-free survival and overall survival. In contrast, stromal levels of PD-L1 and Galectin-9 were associated with better prognosis. This study provides insights into the immunosuppressive mechanism in chordoma and may contribute to the development of improved immunotherapy approaches.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Integrative analysis from multi-center studies identities a consensus machine learning-derived lncRNA signature for stage II/III colorectal cancer

Zaoqu Liu et al.

Summary: This study comprehensively identified recurrence-related lncRNAs and determined an optimal machine learning-derived lncRNA signature for predicting the risk of recurrence in colorectal cancer patients. The signature was independent of common clinical and molecular features and showed better performance than these variables. Further validation confirmed these findings and demonstrated that patients with a high signature benefited more from a certain chemotherapy drug, while patients with a low signature were more sensitive to another drug.

EBIOMEDICINE (2022)

Add to Collection

Review Oncology

(Im)maturity in Tumor Ecosystem

Keywan Mortezaee et al.

Summary: The immaturity of cells in tumors and the cellular tumor ecosystem plays a significant role in cancer progression. Understanding the mechanisms behind this immaturity can lead to new therapeutic approaches in cancer treatment.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Human Endogenous Retrovirus-H Long Terminal Repeat-Associating Protein 2 Possesses Prognostic Significance and Promotes Progression of Papillary Thyroid Cancer

Yongzhi Niu et al.

Summary: This study investigates the clinical significance and biological function of HHLA2 in papillary thyroid carcinoma (PTC), and finds that HHLA2 is upregulated in PTC and associated with lymph node metastasis and advanced TNM stage. HHLA2 serves as an independent prognostic factor and promotes tumor progression in PTC, suggesting it as a potential therapeutic target.

INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2022)

Add to Collection

Article Multidisciplinary Sciences

The immune checkpoint B7x expands tumor-infiltrating Tregs and promotes resistance to anti-CTLA-4 therapy

Peter John et al.

Summary: B7x, an immune checkpoint molecule, promotes the conversion of CD4+ T cells into regulatory T cells within the tumor microenvironment. It induces transcriptomic changes in regulatory T cells, altering their phenotype to an activated and suppressive state. B7x-mediated regulation reduces the efficacy of anti-CTLA-4 treatment, but combination therapy with anti-B7x and anti-CTLA-4 overcomes this resistance and shows synergistic therapeutic efficacy.

NATURE COMMUNICATIONS (2022)

Add to Collection

Review Oncology

Roles for macrophage-polarizing interleukins in cancer immunity and immunotherapy

Keywan Mortezaee et al.

Summary: Macrophages play a crucial role in tumor immunity by releasing cytokines to modulate the tumor microenvironment. The phenotype of macrophages is influenced by cytokine family members, which determine the immune response. Understanding this aspect is important for developing effective cancer immunotherapy and minimizing adverse effects associated with cytokine therapy.

CELLULAR ONCOLOGY (2022)

Add to Collection

Article Oncology

A Novel Machine Learning 13-Gene Signature: Improving Risk Analysis and Survival Prediction for Clear Cell Renal Cell Carcinoma Patients

Patrick Terrematte et al.

Summary: This study used machine learning to identify a gene signature for clear cell renal cell carcinoma (ccRCC) that can accurately predict patient outcomes. The 13-gene signature could potentially be used in personalized medicine for clinical practice.

CANCERS (2022)

Add to Collection

Article Medicine, Research & Experimental

The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma

Dawei Zhu et al.

Summary: As an important regulator of N6-methyladenosine (m(6)A), abnormal expression of methyltransferase-like protein 3 (METTL3) has been observed in certain human cancers. This study investigated the expression and clinical implications of METTL3 in clear-cell renal cell carcinoma (ccRCC) and elucidated its mechanism of action. The results showed that METTL3 expression was significantly higher in ccRCC tissues compared to adjacent normal tissues. Patients with low METTL3 expression had significantly better overall survival. Depletion of METTL3 inhibited cell viability, migration, and invasion in ccRCC cell lines. METTL3 was found to regulate HHLA2 expression via m(6)A modification of HHLA2 mRNA. Overexpression of HHLA2 reversed the inhibition of cellular functions mediated by METTL3 depletion. The findings suggest that METTL3 is an important prognostic predictor for ccRCC patients and provide new insights into targeted therapeutic strategies against this malignancy.

JOURNAL OF TRANSLATIONAL MEDICINE (2022)

Add to Collection

Article Medicine, General & Internal

Single-cell RNA sequencing highlights the functional role of human endogenous retroviruses in gallbladder cancer

Jinghan Wang et al.

Summary: This study investigates the role of human endogenous retroviruses in gallbladder cancer, aiming to find new diagnostic and therapeutic approaches.

EBIOMEDICINE (2022)

Add to Collection

Meeting Abstract Oncology

NPX267, A FIRST-IN-CLASS MONOCLONAL ANTIBODY TARGETING KIR3DL3, BLOCKS HHLA2-MEDIATED IMMUNOSUPPRESSION AND POTENTIATES T AND NK CELL-MEDIATED ANTITUMOR IMMUNITY

McKenna Lamb et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

High expression of HHLA2 predicts poor prognosis in medullary thyroid carcinoma

Yongzhi Niu et al.

Summary: This study investigated the expression of human endogenous retrovirus-H long terminal repeat-associating protein 2 in medullary thyroid carcinoma and its relationship with clinicopathologic factors and prognosis. The results showed that high expression of human endogenous retrovirus-H long terminal repeat-associating protein 2 was associated with lymph node metastasis and advanced cancer stages. It also acted as an independent prognostic factor for disease-free survival in medullary thyroid carcinoma patients.

JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Immunology

B7-H7 (HHLA2) inhibits T-cell activation and proliferation in the presence of TCR and CD28 signaling

Sadiye Amcaoglu Rieder et al.

Summary: B7-H7 induced transcriptomic changes are insufficient to support full costimulation with TCR signaling, inhibiting T-cell activation and proliferation in the presence of TCR and CD28 signaling.

CELLULAR & MOLECULAR IMMUNOLOGY (2021)

Add to Collection

Review Biochemistry & Molecular Biology

Enriched cancer stem cells, dense stroma, and cold immunity: Interrelated events in pancreatic cancer

Keywan Mortezaee

Summary: Cold tumors, such as those in the pancreas, are characterized by low mutational burden and infiltration of effector T cells. The dense stroma in such tumors not only acts as a barrier for drug penetration but also creates an immunosuppressive tumor microenvironment, leading to low responses to immunotherapy. Cancer stem cells within the tumor microenvironment negatively impact the activity of the antitumor immune system, highlighting the importance of understanding how desmoplastic aggregates affect their functionality in promoting cold tumor immunity.

JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY (2021)

Add to Collection

Article Oncology

KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory for Pathway to PD1

Rupal S. Bhatt et al.

Summary: The study identified KIR3DL3 as an inhibitory receptor for HHLA2, suggesting that blocking both PD1 and KIR3DL3 pathways may be a more effective way to reverse tumor immune evasion.

CANCER IMMUNOLOGY RESEARCH (2021)

Add to Collection

Article Medicine, Research & Experimental

H Long Terminal Repeat-Associating 2 (HHLA2) is a Biomarker of Advanced Stage Hepatocellular Carcinoma and Promotes Tumor Cell Development In Vitro

Min Luo et al.

Summary: The study found that HHLA2 is highly expressed in HCC tissues compared to para-carcinoma liver tissues, indicating its significant role in HCC development and progression. Due to its high expression, HHLA2 may serve as a potential prognostic biomarker for HCC.

MEDICAL SCIENCE MONITOR (2021)

Add to Collection

Article Oncology

HHLA2 predicts better survival and exhibits inhibited proliferation in epithelial ovarian cancer

Guocai Xu et al.

Summary: HHLA2 expression in ovarian cancer is associated with tumor differentiation, high CD8(+) TIL levels, and improved survival. Overexpressing HHLA2 inhibits the proliferation of ovarian cancer cells.

CANCER CELL INTERNATIONAL (2021)

Add to Collection

Review Oncology

Organ tropism in solid tumor metastasis: an updated review

Keywan Mortezaee

Summary: Tumors of solid organs have a tendency to metastasize to specific organs, relying on the plasticity of tumor cells to reshape their epigenetic landscape and successfully colonize new areas.

FUTURE ONCOLOGY (2021)

Add to Collection

Review Cell Biology

Normalization in tumor ecosystem: Opportunities and challenges

Keywan Mortezaee

Summary: Current research in cancer therapy focuses on reversing abnormalities within the tumor stroma by strategies such as vascular normalization, metabolic modulation, balancing cellular dispersion, and pH and O-2 delivery balance to restore the ecosystem balance for long-lasting effects on tumors.

CELL BIOLOGY INTERNATIONAL (2021)

Add to Collection

Article Medicine, Research & Experimental

Myeloid-derived suppressor cells in cancer immunotherapy-clinical perspectives

Keywan Mortezaee

Summary: Myeloid-derived suppressor cells (MDSCs) are a group of immature immune cells that significantly increase in cancer patients, releasing factors that impact tumor-related events such as metastasis and immune evasion, and can serve as an indicator of tumor prognosis. They can be targeted in combination with current immunotherapies to enhance the immune system's response against tumors.

LIFE SCIENCES (2021)

Add to Collection

Article Oncology

HHLA2 deficiency inhibits non-small cell lung cancer progression and THP-1 macrophage M2 polarization

Wenjie Sun et al.

Summary: The study revealed the upregulation of HHLA2 in NSCLC is associated with tumor growth and M2 polarization of macrophages. Additionally, HHLA2 may serve as a therapeutic target and promising prognostic biomarker in NSCLC.

CANCER MEDICINE (2021)

Add to Collection

Article Immunology

B7-H7 Is Inducible on T Cells to Regulate Their Immune Response and Serves as a Marker for Exhaustion

Khang Luu et al.

Summary: The discovery of B7-H7 as an immune checkpoint highlights its potential as a target for immunotherapy, with conflicting data regarding its function suggesting it can have both stimulatory and inhibitory effects. B7-H7 is preferentially expressed on exhausted Th1 and Tc1 cells, and blockade of B7-H7 enhances T cell proliferation and activation, making it a potential biomarker for selecting active effector T cells in adoptive cell transfer therapy.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Article Immunology

KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target

Yao Wei et al.

Summary: HHLA2 is a promising target for cancer immunotherapy due to its coinhibitory function and overexpression in human cancers. The KIR3DL3-HHLA2 pathway may be a potential immunotherapeutic target for cancer.

SCIENCE IMMUNOLOGY (2021)

Add to Collection

Article Immunology

Clinical Significance of the HHLA2 Protein in Hepatocellular Carcinoma and the Tumor Microenvironment

Min Luo et al.

Summary: Higher levels of HHLA2 in HCC are associated with advanced clinical cancer stage, multiple tumors, poor tumor differentiation, microvascular invasion, and hepatic capsule invasion. High levels of HHLA2 are correlated significantly with density of TILs, but not with PD-L1 levels. High HHLA2 levels are associated with worse prognosis.

JOURNAL OF INFLAMMATION RESEARCH (2021)

Add to Collection

Article Cell Biology

HHLA2 overexpression is a novel biomarker of malignant status and poor prognosis in gastric cancer

Li Wei et al.

HUMAN CELL (2020)

Add to Collection

Article Oncology

HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis

Patrick P. C. Boor et al.

BRITISH JOURNAL OF CANCER (2020)

Add to Collection

Article Oncology

HHLA2 and PD-L1 co-expression predicts poor prognosis in patients with clear cell renal cell carcinoma

Qiang-Hua Zhou et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2020)

Add to Collection

Article Cell Biology

Over-Expression and Prognostic Significance of HHLA2, a New Immune Checkpoint Molecule, in Human Clear Cell Renal Cell Carcinoma

Zhen Zhang et al.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2020)

Add to Collection

Article Oncology

Identification of methylation-driven genes related to the prognosis of papillary renal cell carcinoma: a study based on The Cancer Genome Atlas

Zeyu Liu et al.

CANCER CELL INTERNATIONAL (2020)

Add to Collection

Article Oncology

B7-H7 is a prognostic biomarker in epithelial ovarian cancer

Yuanyuan Fu et al.

TRANSLATIONAL CANCER RESEARCH (2020)

Add to Collection

Article Genetics & Heredity

Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target

Dongming Chen et al.

JOURNAL OF MEDICAL GENETICS (2019)

Add to Collection

Article Biochemistry & Molecular Biology

Disruption of the redox balance with either oxidative or anti-oxidative overloading as a promising target for cancer therapy

Bagher Farhood et al.

JOURNAL OF CELLULAR BIOCHEMISTRY (2019)

Add to Collection

Article Oncology

Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells

Hongwei Du et al.

CANCER CELL (2019)

Add to Collection

Article Oncology

HHLA2 is a novel immune checkpoint protein in pancreatic ductal adenocarcinoma and predicts post-surgical survival

Han Yan et al.

CANCER LETTERS (2019)

Add to Collection

Article Oncology

HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1

Chu-Yu Jing et al.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)

Add to Collection

Article Oncology

Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients

Lujun Chen et al.

CANCER CELL INTERNATIONAL (2019)

Add to Collection

Article Oncology

B7-H5/CD28H is a co-stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma

Qi Chen et al.

CANCER SCIENCE (2019)

Add to Collection

Article Oncology

CAR T Cells Targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors

Robbie G. Majzner et al.

CLINICAL CANCER RESEARCH (2019)

Add to Collection

Article Oncology

CD28H expression identifies resident memory CD8+T cells with less cytotoxicity in human peripheral tissues and cancers

Yu Tian et al.

ONCOIMMUNOLOGY (2019)

Add to Collection

Article Oncology

Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers

Haiying Cheng et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Immunology

Impaired natural killer cell subset phenotypes in human obesity

Ina Baehr et al.

IMMUNOLOGIC RESEARCH (2018)

Add to Collection

Article Biotechnology & Applied Microbiology

Overexpression of HHLA2, a member of the B7 family, is associated with worse survival in human colorectal carcinoma

Ziwen Zhu et al.

ONCOTARGETS AND THERAPY (2018)

Add to Collection

Review Oncology

New B7 Family Checkpoints in Human Cancers

Ling Ni et al.

MOLECULAR CANCER THERAPEUTICS (2017)

Add to Collection

Review Immunology

Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family

Frank A. Schildberg et al.

IMMUNITY (2016)

Add to Collection

Editorial Material Oncology

HHLA2 and TMIGD2: new immunotherapeutic targets of the B7 and CD28 families

Murali Janakiram et al.

ONCOIMMUNOLOGY (2015)

Add to Collection

Article Oncology

Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 Protein

Murali Janakiram et al.

CLINICAL CANCER RESEARCH (2015)

Add to Collection

Article Multidisciplinary Sciences

HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function

Ruihua Zhao et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)

Add to Collection

© Peeref 2019-2024. All rights reserved.